Alain Matagne

Summary

Publications

  1. doi request reprint Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy
    Alain Matagne
    CNS Research, UCB Pharma SA, Chemin du Foriest, B 1420 Braine l Alleud, Belgium
    Eur J Pharmacol 614:30-7. 2009
  2. doi request reprint Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam
    Rafal M Kaminski
    UCB Pharma S A, CNS Research, B 1420 Braine l Alleud, Belgium
    Epilepsia 50:1729-40. 2009
  3. doi request reprint Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats
    Doru Georg Margineanu
    UCB Pharma SA, CNS Research, B 1420 Braine l Alleud, Belgium
    Brain Res Bull 77:282-5. 2008
  4. doi request reprint Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties
    Michel Gillard
    CNS Research, UCB Pharma SA, Braine l Alleud, Belgium
    Eur J Pharmacol 664:36-44. 2011
  5. doi request reprint Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam
    Rafal M Kaminski
    CNS Research, UCB, B 1420 Braine l Alleud, Belgium
    Epilepsia 50:387-97. 2009
  6. doi request reprint SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy
    Rafal M Kaminski
    CNS Research, UCB Pharma SA, Chemin du Foriest R9, Braine l Alleud, Belgium
    Neuropharmacology 54:715-20. 2008
  7. ncbi request reprint Pilocarpine-induced epileptogenesis in the rat: impact of initial duration of status epilepticus on electrophysiological and neuropathological alterations
    Henrik Klitgaard
    Preclinical CNS Research, UCB SA Pharma Sector, Chemin du Foriest, B 1420 Braine l Alleud, Belgium
    Epilepsy Res 51:93-107. 2002
  8. ncbi request reprint Use of epileptic animals for adverse effect testing
    Henrik Klitgaard
    Preclinical CNS Research, UCB S A Pharma Sector, Chemin du Foriest, Braine l Alleud, Belgium
    Epilepsy Res 50:55-65. 2002

Detail Information

Publications8

  1. doi request reprint Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy
    Alain Matagne
    CNS Research, UCB Pharma SA, Chemin du Foriest, B 1420 Braine l Alleud, Belgium
    Eur J Pharmacol 614:30-7. 2009
    ..These results suggest that seletracetam may represent an effective and very well tolerated broad-spectrum agent for the symptomatic treatment of epilepsy...
  2. doi request reprint Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam
    Rafal M Kaminski
    UCB Pharma S A, CNS Research, B 1420 Braine l Alleud, Belgium
    Epilepsia 50:1729-40. 2009
    ..In the present study we characterized SV2A (+/-) heterozygous mice in several seizure models and tested if the anticonvulsant efficacy of levetiracetam is reduced in these mice...
  3. doi request reprint Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats
    Doru Georg Margineanu
    UCB Pharma SA, CNS Research, B 1420 Braine l Alleud, Belgium
    Brain Res Bull 77:282-5. 2008
    ..The present results indicate that chronic treatment with levetiracetam completely inhibits the development of hippocampal hyperexcitability following pilocarpine-induced SE...
  4. doi request reprint Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties
    Michel Gillard
    CNS Research, UCB Pharma SA, Braine l Alleud, Belgium
    Eur J Pharmacol 664:36-44. 2011
    ....
  5. doi request reprint Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam
    Rafal M Kaminski
    CNS Research, UCB, B 1420 Braine l Alleud, Belgium
    Epilepsia 50:387-97. 2009
    ..Moreover, combinations of levetiracetam with clinically used AEDs that enhance GABAergic inhibition may be considered for rational polytherapy, which is often necessary in drug-resistant patients...
  6. doi request reprint SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy
    Rafal M Kaminski
    CNS Research, UCB Pharma SA, Chemin du Foriest R9, Braine l Alleud, Belgium
    Neuropharmacology 54:715-20. 2008
    ....
  7. ncbi request reprint Pilocarpine-induced epileptogenesis in the rat: impact of initial duration of status epilepticus on electrophysiological and neuropathological alterations
    Henrik Klitgaard
    Preclinical CNS Research, UCB SA Pharma Sector, Chemin du Foriest, B 1420 Braine l Alleud, Belgium
    Epilepsy Res 51:93-107. 2002
    ..Among these, hippocampal field potentials appear to represent the most sensitive marker, potentially useful for pharmacological evaluation of drugs with putative antiepileptogenic properties...
  8. ncbi request reprint Use of epileptic animals for adverse effect testing
    Henrik Klitgaard
    Preclinical CNS Research, UCB S A Pharma Sector, Chemin du Foriest, Braine l Alleud, Belgium
    Epilepsy Res 50:55-65. 2002
    ..In that respect, limbic kindling appears to represent a sensitive and relevant approach...